Identifying Potential Effects of Liraglutide on Degenerative Changes

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice.

The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Informed consent before study-related activity

• Adult competent persons

• Diagnosed with diagnosed Alzheimer's disease. With a MMSE score between 18-21 the diagnosis should be entirely based on the clinic, while diagnosis by MMSE with a score > 22 should be diagnosed by spinal puncture

• Age ≥ 50 years and ≤ 80 years

• Caucasians

Exclusion Criteria:

• Diabetes mellitus

• Clinically significant liver (s-ALT > 2 times upper reference or creatinine-clearance < 30 mL / min, assessed on Cockcroft-Gault normogram)

• Clinically significant anemia

• Other clinically relevant abnormal biochemical value

• Current or former presence of one of the following diseases with clinical relevance:

1. another CNS-illness other than diagnosed depression treated with SSRI or SSRI similar drugs.

2. liver disease

3. kidney disease

4. endocrinological disease other than well controlled hypothyroidism

• Current or history of chronic or acute pancreatitis

• Any disease which the investigators believe may affect the study

• Patients treated with TCA or neuroleptics

• Known abuse of alcohol or drugs

• Known allergy to liraglutide or any of the other components (disodium phosphate dihydrate, propylene glycol and phenol)

• Participation in a clinical trial less than 3 months before inclusion in this study

• Persons who within a period of the last 2 years have participated in scientific experiments involving the use of isotopes, or who have had greater diagnostic tests performed using applied ionizing radiation

• If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable

• Claustrophobia or other missing cooperation

• Severe overweight > 130kg

• Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body

• Significant abnormities in the brain detected by MR scanning